US approval for migraine treatment

I reported previously (see here) on the AJOVY fremanezumab migraine treatment from Israel’s Teva. The US FDA has just given approval for AJOVY – the only anti-CGRP treatment for the prevention of migraine.  About 40% of migraine sufferers may be candidates for this treatment.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *